Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Holding SA RLFTF

Healthcare Biotechnology
Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.


Recent & Breaking News (OTCQB:RLFTF)

NeuroRx and Relief Therapeutics announce continuation of RLF-100(TM) trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

PR Newswire November 5, 2020

Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team

Accesswire November 4, 2020

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

PR Newswire October 13, 2020

Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer

Accesswire October 8, 2020

NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100(TM) (aviptadil)

PR Newswire September 30, 2020

Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

Accesswire September 28, 2020

NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

PR Newswire September 23, 2020

Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners

PR Newswire September 21, 2020

Relief Reports Half-Year 2020 Results

Accesswire September 15, 2020

Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer

Accesswire September 4, 2020

Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM

Accesswire August 31, 2020

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

PR Newswire August 6, 2020

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

PR Newswire August 2, 2020

FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19: Currently in development by NeuroRx and Relief Therapeutics under Fast Track Designation

PR Newswire July 29, 2020